Nucleix For Profit

Nucleix is a company that develops, manufactures and markets non-invasive cancer tests using their unique technology. They aim to detect cancer earlier when treatment can be most effective for patients. Their products include Bladder EpiCheck and Lung EpiCheck. Bladder EpiCheck is CE-marked and available in Europe for primary and recurrent bladder cancer and upper tract urinary cancer, and FDA 510(k) cleared for bladder cancer recurrence in the United States. Lung EpiCheck is in development. They have collaborations with leading medical centers, organizations, and laboratories worldwide. They have offices in the United States and Israel. Contact info: US Office: Phone +858-283-3398, 10675 Sorrento Valley Road, Ste 250, San Diego, CA 92121Israel Office: Phone +972-8-9161616, Fax +972-8-9166966, 3 Pekeris Street, Rehovot, 7670203, Israel.Email: info@nucleix.com

Investors

Connections from

Funding Status: Seed
Headquarters: Rehovot, HaMerkaz, Israel
Founded Date: 2008-01-01
Investor Type: N/A
Investment Stage: N/A
Technology: Biomarker panels
Employee Number: 11-50
Number Of Exists: 11-50
Estimated Revenue: $12.9Mper year
Industry: Clinical Data Management
Register and Claim Ownership